DYNE THERAPEUTICS INC

12,05

20-мая-25 13:56:10

15 мин. задержка

Акции

+0,39

+3,34%

Сегодняшний диапазон

11,45 - 12,10

ISIN

N/A

Источник

NASDAQ

Dyne Therapeutics Announces New Clinical Data from Phase 1/2 DELIVER Trial of DYNE-251 in Duchenne Muscular Dystrophy Demonstrating Unprecedented Dystrophin Expression and Functional Improvement in Multiple Cohorts

03 сен 2024 06:30:00 Источник Nasdaq GlobeNewswire
Dyne Therapeutics to Present at Morgan Stanley 22nd Annual Global Healthcare Conference

29 авг 2024 07:30:00 Источник Nasdaq GlobeNewswire
Dyne Therapeutics Reports Second Quarter 2024 Financial Results and Recent Business Highlights

12 авг 2024 17:10:00 Источник Nasdaq GlobeNewswire
Dyne Therapeutics Presents New Preclinical Data Demonstrating the Potential of the FORCE™ Platform to Deliver Enzyme Replacement Therapy to Muscle and CNS in Pompe Disease

24 июн 2024 07:30:00 Источник Nasdaq GlobeNewswire
Dyne Therapeutics Presents New Preclinical Data for its Facioscapulohumeral Muscular Dystrophy Program During the FSHD Society International Research Congress

13 июн 2024 16:40:00 Источник Nasdaq GlobeNewswire
Dyne Therapeutics to Present at Jefferies Global Healthcare Conference

30 май 2024 07:30:00 Источник Nasdaq GlobeNewswire
Dyne Therapeutics Announces Closing of Public Offering of Common Stock and Full Exercise by Underwriters of Option to Purchase Additional Shares

28 май 2024 07:30:00 Источник Nasdaq GlobeNewswire
Dyne Therapeutics Announces Pricing of $325.5 Million Public Offering of Common Stock

21 май 2024 20:39:57 Источник Nasdaq GlobeNewswire
Dyne Therapeutics Announces Proposed Public Offering of Common Stock

20 май 2024 16:01:00 Источник Nasdaq GlobeNewswire
Dyne Therapeutics Announces New Clinical Data from ACHIEVE Trial of DYNE-101 in DM1 and DELIVER Trial of DYNE-251 in DMD Demonstrating Compelling Impact on Key Disease Biomarkers and Improvement in Multiple Functional Endpoints

20 май 2024 06:30:06 Источник Nasdaq GlobeNewswire
Dyne Therapeutics to Host Virtual Investor Event to Review New Clinical Data from the ACHIEVE and DELIVER Trials Tomorrow, May 20 at 8:00 a.m. ET

19 май 2024 08:00:00 Источник Nasdaq GlobeNewswire
Dyne Therapeutics Reports First Quarter 2024 Financial Results and Recent Business Highlights

02 май 2024 16:10:00 Источник Nasdaq GlobeNewswire
Dyne Therapeutics Reports Inducement Grant Under Nasdaq Listing Rule 5635(c)(4) to Newly Appointed President and Chief Executive Officer

27 мар 2024 16:05:00 Источник Nasdaq GlobeNewswire
Dyne Therapeutics to Present at the Cantor Virtual Muscular Dystrophy Symposium

27 мар 2024 08:30:00 Источник Nasdaq GlobeNewswire
Dyne Therapeutics Announces CEO Transition

25 мар 2024 07:30:00 Источник Nasdaq GlobeNewswire
Dyne Therapeutics to Present at Stifel 2024 Virtual CNS Days

13 мар 2024 07:30:00 Источник Nasdaq GlobeNewswire
Dyne Therapeutics Reports Fourth Quarter and Full Year 2023 Financial Results and Recent Business Highlights

05 мар 2024 07:30:00 Источник Nasdaq GlobeNewswire
Dyne Therapeutics Announces Upcoming Presentations on Initial Clinical Data From its ACHIEVE Trial in DM1 Patients and DELIVER Trial in DMD Patients at the 2024 Muscular Dystrophy Association Clinical & Scientific Conference

14 фев 2024 16:15:16 Источник Nasdaq GlobeNewswire
Dyne Therapeutics to Present at February Investor Conferences

01 фев 2024 07:30:00 Источник Nasdaq GlobeNewswire
Dyne Therapeutics Announces Closing of Public Offering of Common Stock and Full Exercise by Underwriters of Option to Purchase Additional Shares

11 янв 2024 16:05:00 Источник Nasdaq GlobeNewswire

<<
<
1
2
>

Принимаю NetDania's website uses cookies. By continuing browsing our website, you agree to our Правила в отношении Cookies, Политика конфиденциальности and Правила и условия.